Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Current Leases (2019 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Current Leases for 7 consecutive years, with $416000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Current Leases rose 6.67% to $416000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $416000.0, a 6.67% increase, with the full-year FY2024 number at $398000.0, up 8.15% from a year prior.
  • Current Leases was $416000.0 for Q3 2025 at NovaBay Pharmaceuticals, up from $409000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $485000.0 in Q3 2023 to a low of $195000.0 in Q3 2021.
  • A 5-year average of $394210.5 and a median of $403000.0 in 2025 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: tumbled 51.92% in 2021, then soared 128.21% in 2022.
  • NovaBay Pharmaceuticals' Current Leases stood at $200000.0 in 2021, then soared by 126.5% to $453000.0 in 2022, then decreased by 18.76% to $368000.0 in 2023, then grew by 8.15% to $398000.0 in 2024, then increased by 4.52% to $416000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Current Leases are $416000.0 (Q3 2025), $409000.0 (Q2 2025), and $403000.0 (Q1 2025).